Diagnosis related groups (DRGs) still imperfect, but new system succeeding
This article was originally published in Clinica
Executive Summary
The DRG system is clearly beginning to work in Germany, but the DRG catalogue needs to be improved. So said the federal health ministry's DRG expert Dr Karl-Heinz Tuschen. Speaking at a MedInform/BVMed progress update conference, in Bonn on January 24, he said that the introductory transition phase (to 2009) will be most useful if the system progressively changes from a budget- to a prices-based system, and more services are fully integrated into the full DRGs. Transparency of the system has clearly improved.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.